دورية أكاديمية
Proteasome Inhibitor YSY01A Enhances Cisplatin Cytotoxicity in Cisplatin-Resistant Human Ovarian Cancer Cells.
| العنوان: | Proteasome Inhibitor YSY01A Enhances Cisplatin Cytotoxicity in Cisplatin-Resistant Human Ovarian Cancer Cells. |
|---|---|
| المؤلفون: | Huang W; 1. State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China., Zhou Q; 1. State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China., Yuan X; 1. State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China., Ge ZM; 2. Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China., Ran FX; 1. State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China., Yang HY; 3. Department of Liver Surgery, Peking Union Medical College (PUMC) Hospital, Chinese Academy of Medical Sciences and PUMC, Beijing 100730, China., Qiang GL; 4. Department of Thoracic Surgery, China-Japan Friendship Hospital, Beijing 100029, China., Li RT; 2. Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China., Cui JR; 1. State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China. |
| المصدر: | Journal of Cancer [J Cancer] 2016 Jun 06; Vol. 7 (9), pp. 1133-41. Date of Electronic Publication: 2016 Jun 06 (Print Publication: 2016). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Ivyspring International Publisher Country of Publication: Australia NLM ID: 101535920 Publication Model: eCollection Cited Medium: Print ISSN: 1837-9664 (Print) Linking ISSN: 18379664 NLM ISO Abbreviation: J Cancer Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Wyoming, N.S.W. : Ivyspring International Publisher, 2010- |
| مستخلص: | Cisplatin is one of the most common drugs used for treatment of solid tumors such as ovarian cancer. Unfortunately, the development of resistance against this cytotoxic agent limits its clinical use. Here we report that YSY01A, a novel proteasome inhibitor, is capable of suppressing survival of cisplatin-resistant ovarian cancer cells by inducing apoptosis. And YSY01A treatment enhances the cytotoxicity of cisplatin in drug-resistant ovarian cancer cells. Specifically, YSY01A abrogates regulatory proteins important for cell proliferation and anti-apoptosis including NF-κB p65 and STAT3, resulting in down-regulation of Bcl-2. A dramatic increase in cisplatin uptake was also observed by inductively coupled plasma-mass spectrometry following exposure to YSY01A. Taken together, YSY01A serves as a potential candidate for further development as anticancer therapeutics targeting the proteasome. |
| References: | Leukemia. 2012 Apr;26(4):757-68. (PMID: 21941364) Curr Cancer Drug Targets. 2011 Mar;11(3):254-84. (PMID: 21247382) J Cancer. 2015 Jun 11;6(8):701-8. (PMID: 26185531) Ann Pharmacother. 2013 Jan;47(1):56-62. (PMID: 23300152) Gynecol Oncol. 2009 Jan;112(1):275-81. (PMID: 18977023) Curr Cancer Drug Targets. 2011 Mar;11(3):239-53. (PMID: 21247388) Leukemia. 2003 Jul;17(7):1349-56. (PMID: 12835724) Clin Cancer Res. 2009 Jan 15;15(2):553-60. (PMID: 19147760) J Int Med Res. 2013 Oct;41(5):1505-19. (PMID: 23975859) Oncogene. 2002 Oct 31;21(50):7611-8. (PMID: 12400004) ACS Chem Biol. 2014 May 16;9(5):1188-96. (PMID: 24661007) Genet Mol Res. 2015 Mar 30;14(1):2450-60. (PMID: 25867391) Curr Cancer Drug Targets. 2014;14 (6):517-36. (PMID: 25092212) Oncol Rep. 2012 Jul;28(1):27-32. (PMID: 22562377) Oncogene. 2012 Apr 12;31(15):1869-83. (PMID: 21892204) Oncogene. 2012 May 3;31(18):2309-22. (PMID: 21909139) Cytokine Growth Factor Rev. 2010 Feb;21(1):11-9. (PMID: 20018552) Oncogene. 2016 Feb 11;35(6):783-92. (PMID: 26073084) Clin Cancer Res. 2005 Dec 1;11(23):8398-402. (PMID: 16322301) J Exp Clin Cancer Res. 2011 Oct 04;30:91. (PMID: 21967738) Cell Signal. 2013 Jan;25(1):308-18. (PMID: 23079083) J Cancer. 2015 Feb 06;6(4):319-26. (PMID: 25767601) Bioorg Med Chem. 2009 Oct 1;17(19):6851-61. (PMID: 19747832) Oncol Lett. 2015 Jul;10(1):560-564. (PMID: 26171069) Cell Biochem Biophys. 2015 May;72 (1):203-13. (PMID: 25510462) Br J Cancer. 2003 Dec;89 Suppl 3:S23-8. (PMID: 14661043) Blood. 2006 Jun 15;107(12):4907-16. (PMID: 16507771) J Natl Cancer Inst. 2011 Jul 6;103(13):1007-17. (PMID: 21606441) Eur J Pharmacol. 2011 Mar 1;654(1):17-25. (PMID: 21184754) Drug Resist Updat. 2008 Aug-Oct;11(4-5):164-79. (PMID: 18818117) Mol Med Rep. 2015 Jan;11(1):189-95. (PMID: 25323748) World J Gastroenterol. 2007 Jan 14;13(2):250-6. (PMID: 17226904) J Biol Chem. 2006 Oct 20;281(42):31440-7. (PMID: 16928686) Onco Targets Ther. 2014 Sep 29;7:1793-800. (PMID: 25302026) Biochim Biophys Acta. 2012 Jun;1823(6):1082-91. (PMID: 22504301) Pharmacol Rev. 2012 Jul;64(3):706-21. (PMID: 22659329) Am J Health Syst Pharm. 2015 Mar 1;72(5):353-60. (PMID: 25694410) |
| فهرسة مساهمة: | Keywords: NF-κB and STAT3; YSY01A; apoptosis; cisplatin resistance; ovarian cancer; proteasome inhibitor |
| تواريخ الأحداث: | Date Created: 20160622 Date Completed: 20160621 Latest Revision: 20201001 |
| رمز التحديث: | 20221213 |
| مُعرف محوري في PubMed: | PMC4911881 |
| DOI: | 10.7150/jca.14519 |
| PMID: | 27326257 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1837-9664 |
|---|---|
| DOI: | 10.7150/jca.14519 |